This week Eli Lilly LLYannounced an all-cash deal tobuy immuno-oncology biotech, ARMO Biosciences, Inc. ARMO. J&J’s JNJmultiple myeloma drug Darzalex gained FDA approval for combination use in first-line setting while Roche RHHBYannounced a couple of regulatory/pipeline updates on its PD-L1 inhibitor, Tecentriq.
AstraZeneca AZNsold rights to a schizophrenia product and its PARP inhibitor, Lynparza gained marketing approval in the EU.Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться